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httpsWHAT THIS PAPER ADDS
This study analysed risk factors for the occurrence of acute kidney injury (AKI) and long-term renal function
deterioration following endovascular aneurysm repair. Besides peri-operative complications this study identified
the use of angiotensin II receptor blockers as a risk factor for AKI and the presence of renal artery stenosis as a
risk factor for long-term renal function deterioration. Better understanding of these pathophysiological mech-
anisms could help to implement preventive strategies.Objective/Background: Endovascular aneurysm repair (EVAR) may be associated with renal injury and more
insight is needed into potential risk factors. The aim was to identify clinical, anatomical, and peri-procedural
parameters as potential risk factors for the occurrence of acute kidney injury (AKI) and to evaluate chronic kidney
disease (CKD) after EVAR.
Methods: A cohort of 212 consecutive patients who underwent elective EVAR for abdominal aortic aneurysm
from January 2009 to October 2016 was included. A subgroup of 149 patients with 2 years follow-up was
compared with a set of 135 non-operated aneurysm patients with smaller aneurysms (similar cardiovascular risk
profile) to assess CKD. Primary outcomes were AKI (Acute Kidney Injury Network criteria) and CKD measured by
estimated glomerular filtration rate (Kidney Disease Improving Global Outcomes guidelines). For AKI, candidate
risk factors were identified by univariate and multivariate logistic regression analysis; for chronic renal function
decline, risk factors were identified using Cox regression analysis.
Results: AKI occurred in 30 patients (15%). On multivariate analysis, the use of angiotensin II blocker (odds ratio
[OR] 4.08, 95% confidence interval [CI] 1.38e12.07) and peri-operative complications (OR 3.12, 95% CI 1.20e
8.10) were independent risk factors for AKI, whereas statin use was a protective factor (OR 0.19, 95% CI 0.07e
0.52). EVAR resulted in a significant increase (23.5%) in the occurrence of CKD compared with the control group
(6.7%; p <.001). On univariate and multivariate Cox regression the risk factors: aortic neck diameter (per mm
increase) (hazard ratio [HR] 1.13, 95% CI 1.02e1.25), renal artery stenosis >50% (HR 2.24, 95% CI 1.05e4.79),
and the occurrence of AKI (HR 2.19, 95% CI 0.99e4.85) were significant predictors of CKD.
Conclusion: This study identified use of angiotensin II blockers and peri-operative complications as risk factors for
AKI. In addition, the problem of renal function decline after EVAR is highlighted, which indicates that prolonged
protective measures (e.g., in those patients at high risk) over time are needed to improve patient outcomes.
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taneous coronary intervention and elective coronary bypass
grafting, patients with AKI have a 20 fold increased risk of
post-procedure mortality.1,2
In open abdominal infrarenal aortic surgery, post-operative
renal dysfunction is also associated with increased in hospital
mortality.3 Furthermore, other studies have documented
increased long-termmortality associated with the occurrence
of AKI after cardiovascular procedures.4,5 In aneurysm treat-
ment, studies have focused on the differences in occurrence
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aneurysm repair (EVAR) and it is clear that both treatment
approaches carry a risk of AKI.3,6,7 After EVAR, a wide range of
AKI incidences have been reported (3e19%), depending on
the criteria used. However, more recent data using the Kidney
Disease Improving Global Outcomes (KDIGO) guidelines sug-
gested that about 15% to 20% of all EVAR patients develop
AKI.6,8,9 With a shift towards more endovascular procedures
and, consequently, more re-interventions in aneurysm treat-
ment, extra attention is being paid to the problem of EVAR
related long-term renal function decline. A recent systematic
review and meta-analysis on renal function after EVAR indi-
cated that there is a significant deterioration in renal function
in the follow-up period.10 However, it is not clear whether the
EVAR procedure itself or the cardiovascular risk profile of the
patient and/or re-interventions is affecting long-term renal
function. Compared with open aneurysm repair, EVAR is
associated with fewer operative haemodynamic changes that
have an impact on renal function. However, EVAR is accom-
panied by other potential insults to the kidneys, such as
contrast material and microemboli.11 Recent studies have
described reduced renal function and poor cardiovascular
reserve as significant risk factors for AKI after EVAR.12,13 Other
studies showed contradictory results with regard to whether
suprarenal graft fixation might be associated with renal
function decline.9,14 In order to reduce the occurrence of AKI
in endovascular aneurysm treatment more studies are
needed to unravel its mechanism and elucidate specific risk
factors. Moreover, additional knowledge is needed on po-
tential decline in renal function during follow-up. Therefore,
this study examined the occurrence of post-operative AKI
after EVAR and evaluated risk factors associated with AKI. In
addition, by using a control group of non-operated aneurysm
patients, this study examined clinically relevant renal function
decline during follow-up.MATERIAL AND METHODS
Study population
This study was based on a retrospective analysis of a cohort
of 212 consecutive patients who underwent elective EVAR
for infrarenal aortic or iliac aneurysm from January 2009 to
October 2016 at the HAGA Teaching Hospital, The Hague,
The Netherlands. This retrospective study was approved by
the local ethical committee of HAGA Hospital which issued a
waiver for informed consent. Data were derived from
electronic patient records, which included clinical data,
imaging studies from the PACS image storage system, and
laboratory values (collected as part of routine patient care).
Patients treated for a ruptured abdominal aortic aneurysm,
those treated with fenestrated/ branched or chimney stent
grafts, and patients who were on pre-operative dialysis
were excluded (Fig. 1).Study outcomes
The primary outcome of this study was occurrence of AKI in
the post-operative period. Secondary outcome was detailsof clinically relevant renal function decline 2 years after the
procedure. AKI was defined using Acute Kidney Injury
Network criteria (KDIGO; www.kdigo.org). AKI (stage 1) is
present when an abrupt (in 48 hours) reduction in kidney
function results in an absolute increase in serum creatinine
of  0.3 mg/dL (26 mmol/L) or serum creatinine rise of >
1.5 fold from the reference value, known to have occurred
within 1week. The highest level of creatinine within this
period after EVAR was used to evaluate the presence of
AKI.15,16 Increase in serum creatinine of > 2e3 fold
compared with baseline is classified as stage 2 and more
than threefold as stage 3 AKI. The evaluation of renal
function during follow-up was based on estimated glomer-
ular filtration rate (eGFR; mL/minute/1.73 m2). eGFR was
determined using the abbreviated Modification of Diet in
Renal Disease study equation.17 Clinically relevant renal
function decline was defined using the KDIGO clinical
practice guideline for the evaluation and management of
chronic kidney disease (CKD); renal function is categorized
in several grades, based on eGFR (> 90 [G1], 60e89 [G2],
45e59 [G3a], 30e44 [G3b], 15e29 [G4], < 15 [G5]). A
significant decrease in eGFR is defined as a drop in GFR
category accompanied by a  25% drop in eGFR from
baseline.18
Study outcome assessment
Before patients underwent EVAR, eGFR was determined
pre-operatively (routinely performed and in most patients
prior to contrast imaging studies). Thereafter, renal function
was measured several times during hospital stay (data used
for AKI outcome). After hospital discharge, patients visited
the clinic at regular, protocolled time intervals for follow-up.
To evaluate clinically relevant renal function decline eGFR
values were compared in the follow-up period (at 2 years)
to pre-operative eGFR. eGFR values were also collected in a
control cohort consisting of patients with a small aneurysm.
This control group of patients had an aortic diameter >
3 cm and was periodically examined by ultrasound at the
vascular outpatient clinic. For both EVAR and control pa-
tients, serial measurements of eGFR and follow-up for at
least 2 years were required to be included in these analyses
(comparing clinically relevant renal function decline). Pa-
tients and controls were identified during the same period.
The EVAR procedure using stent grafts with suprarenal
fixation was performed in the operating theatre, usually
under general anaesthesia. All EVAR procedures were per-
formed percutaneously with minimal blood loss and only
patients with a neck length > 1 cm were considered for
EVAR in this series. The details of the procedure have been
described previously.19 Patients with a pre-operative eGFR
< 45 were routinely pre-hydrated with 1 L 0.9% NaCl over
4 hours pre-operatively. All patients received 2 L lactated
Ringer’s solution in the first 24 hours post-operatively.
Risk factors
Candidate risk factors for the development of AKI and
clinically relevant renal function decline included patient
Figure 1. Flowchart of endovascular aneurysm repair patients included in acute kidney injury and chronic kidney disease analyses.
Note. eGFR ¼ estimated glomerular filtration rate. a Thirteen patients did not have adequate kreatinine measurements and were excluded
from the AKI analysis. However, as baseline data were available these patients could be included in the CKD analysis.
714 Randolph G. Statius van Eps et al.demographics, comorbidities (hypertension, diabetes mel-
litus, heart failure, coronary disease, cerebrovascular dis-
ease, peripheral arterial occlusive disease), anatomical
(neck diameter, renal artery stenosis, suprarenal thrombus,
coverage of accessory renal artery), and operative variables
(operating time, contrast volume, complications during
surgery). Post-operative variables (number contrast admin-
istrations, presence of endoleak, re-intervention) were
considered for the long-term renal function decline. These
variables were pre-specified and based on clinical impor-
tance and current knowledge of potential risk factors for
AKI and renal function decline in general.
Presence of hypertension or diabetes was defined based
on the use of antihypertensive medication or use of insulin
and/or antidiabetic agents respectively (current medication
use was extracted from the pre-operative screening form
filled in by the anaesthetist). Classification of patients with
heart failure was based on clear documentation by acardiologist of this condition in the electronic patient record
and usually consisted of previous admissions for heart
failure, chronic medical treatment for this condition, and
participation in an outpatient heart failure program. Pres-
ence of coronary disease was defined by previous coronary
intervention/coronary artery bypass graft or a history of
myocardial infarction and medical treatment for coronary
artery disease. Cerebrovascular disease was defined by a
history of transient ischaemic attack or a cerebrovascular
accident. Patients with peripheral artery disease had a
history of intermittent claudication, critical limb ischaemia,
or were treated by endovascular intervention, bypass, or
amputation for this condition.
Renal artery stenosis was defined as a > 50% stenosis in
one of the renal arteries as observed on the procedural
angiogram. Significant aortic thrombus was defined as >
5 mm thick and > 25% circumference thrombus mass from
the coeliac trunk to above the renal arteries.20 Operative
Acute kidney injury and renal function decline after EVAR 715complications were defined by (i) access site problem
(conversion to open groin after percutaneous approach
owing to bleeding or occlusion); (ii) inadvertent coverage of
main renal artery requiring renal artery stenting; and (iii)
primary type I endoleak requiring additional procedure. The
number of contrast imaging studies using iodinated contrast
material, such as computed tomography angiography and
angiogram, in the follow-up period until the 2 year eGFR
measurement was scored. Re-intervention in the follow-up
period included bypass surgery for iliac limb occlusion and
endovascular treatment of endoleaks.Statistical analysis
Demographic and baseline data were summarized as
mean  SD or proportions, as appropriate. Odds ratio (OR)
with 95% confidence interval (95% CI) for developing AKI for
all risk factors was calculated using univariate logistic
regression. A multivariate logistic regression was performed
to adjust for potential confounders. Risk factors for clinically
relevant renal function decline at 2 years were identified by
performing a Cox regression analysis. Start of follow-up was
defined as the date of surgery; patients were followed until
the end of follow-up, i.e., the occurrence of renal function
decline, loss to follow-up, or death, whichever occurred first.
To compare renal function decline between EVAR and
control patients, mean eGFR decline was calculated for theTable 1. Patient demographics: endovascular aneurysm repair (EVAR)
Demographics EVA
Mean  SD age (y) 75.
Male sex 116
Mean  SD aorta diameter (cm) 5.9
Mean  SD follow-up time (mo) 23.











Angiotensin receptor blockers 38
b blocker 77
GFR decline at 2 y
Clininically relevant renal function decline 35
Mean  SD absolute GFR decline (mL/min) 8
Mean absolute GFR decline difference (95% CI) b 7
Adjusted for baseline GFR 7
þ Adjusted for age and sex 7
þ Adjusted for follow-up time 8
þ Adjusted for aorta diameter 9
þ Adjusted for b blocker or casbasalate calsium 9
Note. Data are n (%) unless otherwise indicated. GFR ¼ glomerular
ischaemic attack; ACE ¼ angiotensin converting enzyme; CI ¼ confid
in the control group. b Between-group difference (EVAR vs. control grEVAR and control groups. The EVAR and control groups
were compared on baseline characteristics using an un-
paired t-test (for continuous data) and a chi-square test for
categorical variables.
The mean difference in eGFR decline between groups
was estimated using an unpaired t-test. In addition, linear
regression was performed to adjust for age, sex, baseline
eGFR, follow-up time in months, aorta diameter, and use of
medication. All analyses were performed using SPSS Sta-
tistics for Windows version 23.0 (IBM, Armonk, NY, USA)




A cohort of 212 EVAR patients (42 females) aged 75  8
years were included in the analyses for developing AKI.
From this cohort, a group of 149 patients who had a follow-
up of at least 2 years with eGFR measurements (or were
lost to follow-up in between) were included for evaluation
of clinically relevant renal function decline. Patients who
died peri-operatively (n ¼ 3) and patients with missing data
for eGFR measurements owing to insufficient follow-up
(n ¼ 60) were excluded (Fig. 1). The control group (non-
operated aneurysm patients) consisted of 135 patients
(Table 1).cohort versus control cohort.
R (n ¼ 149) Control (n ¼ 135) a p
4  7.9 74.7  7.8 .44
(77.9) 113 (83.7) 0.21
 1.0 4.0  0.6 < .001
3  4.5 25.7  4.2 < .001
7  21.2 69.5  22.0 .50
(73.2) 96/134 (71.6) .78
(22.8) 23 (17.0) .22
(8.7) 9/134 (6.7) .53
(14.1) 25/134 (18.7) .30
(17.4) 31/134 (23.1) .23
(75.8) 86/134 (64.2) .03
(75.2) 96/134 (71.6) .50
(26.2) 47/134 (35.1) .10
(25.5) 28/134 (20.9) .36
(51.7) 40/134 (29.9) < .001
(23.5) 9 (6.7) < .001
.8  13.1 1.6  12.0
.25 (-10.24 to e4.26)
.41 (e10.38 to e4.44)
.78 (e10.78 to e4.80)
.27 (e11.36 to e5.17)
.57 (e14.32 to e4.82)
.28 (e14.08 to e4.47)
filtration rate; CVA ¼ cerebrovascular accident; TIA ¼ transient
ence interval. a Some risk factor data were missing for 1 patient
oup).
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The occurrence of AKI could not be determined in 13 cases
owing to missing post-operative creatinine values. AKI was
observed in 30/199 patients (15%). Twenty-seven patients
had stage 1 AKI and in only three patients (1.5%) was there
a more than doubling of post-operative serum creatinine
(stage 2, 3).
The analysis of risk factors for the occurrence of AKI is
presented in Table 2. Pre-operative creatinine, complica-
tion during operation, the presence of suprarenal
thrombus, and the non-use use of statins or of angiotensin
(AT) II blockers (pre-operatively) were associated with AKI
in the univariate analyses. After adjustment for several
confounders (as listed below Table 2) in the multivariate
logistic regression analyses, the effect of complications
during operation and the use of AT II blockers and statins
remained associated with AKI with ORs of 3.12 (95% CI
1.20e8.10), 4.08 (95% CI 1.38e12.07), and 0.19 (0.07e
0.52), respectively (Table 2).
Renal function decline at 2 years
EVAR patients had a similar pre-operative eGFR
(67.7  21.2 mL/minute) to the control group (69.5  22.0
mL/minute) (p ¼ .50). Almost all patient demographics and
comorbidities were comparable between the EVAR and
control group except for aortic diameter (5.9 cm vs. 4.0 cm;
p <.001) and follow-up time in months (mean difference
2.4 months; p <.001). The number of patients and controls
using statins, angiotensin converting enzyme (ACE) in-
hibitors (ACEi), or AT II blockers was comparable, and there
was only a significant difference for the number of beta
blocker and carbasalate calcium users between groups
(Table 1).
The eGFR dropped by 8.8  13.1 mL/minute in the EVAR
group versus 1.6  12.0 mL/minute in the control group
(mean difference 7.25, 95% CI e10.24 to 4.26; p < .001).
This difference gradually increased up to 9.28 mL/minute
(95% CI e14.08 to e4.47) when baseline eGFR, age, sex,
follow-up time, aorta diameter, and medication use were
adjusted for (Table 1).
The occurrence of clinically relevant renal function
decline was significantly more prevalent in the EVAR group
(n ¼ 35/149; 23.5%) compared with the control group
(n ¼ 9/135; 6.7% [p < .001]). Risk factors for clinically
relevant renal function decline in the EVAR group included
the presence of renal artery stenosis (hazard ratio [HR] 2.24,
95% CI 1.05e4.79), higher pre-operative aortic neck diam-
eter (per mm increase; HR 1.13, 95% CI 1.02e1.25), and the
occurrence of AKI (HR 2.19, 95% CI 0.99e4.85) as important
risk factors in the multivariate Cox regression (Table 3).
DISCUSSION
This work corroborates other published studies that EVAR
may be associated with an important effect on renal func-
tion. Together with other published series that used
established criteria to define AKI, it can be stated that about
15% to 20% of EVAR patients develop AKI in the immediatepost-operative period.6,9,12,13 The clinical impact of AKI, as
defined by the current propagated guidelines, following
EVAR has not been well documented and deserves further
study. The study of Saratzis et al. looked at mortality during
follow-up as a secondary outcome and found that there was
a mortality of 32.1% in the AKI group (p < .001) after a
mean follow-up period of 33 months.6
It can be argued that multiple factors play a causal role in
renal injury after EVAR, but the exact role of these potential
factors has not been clearly elucidated.11,21 Better under-
standing of the mechanisms of AKI in EVAR could provide
more insight into preventive strategies. For this reason the
present study considered clinical, anatomical, and peri-
operative factors to comprehensively evaluate potential
risk factors for the occurrence of AKI. A recent study by
Saratzis et al. of a cohort of 947 patients undergoing elec-
tive EVAR demonstrated that reduced pre-operative renal
function was the main factor associated with AKI.12
Although pre-operative increased creatinine levels
appeared to play a role in the present cohort, this was not
found for renal function based on eGFR. It can only be
speculated that routine pre-operative nephrological
consultation and pre-operative hydration in patients with
lower eGFR may have blunted the effect of decreased renal
function in the present series. However, a recent rando-
mised study looking at the effectiveness of hydration in
patients at risk of contrast induced nephropathy (patients
with an eGFR of 30e59 mL/minute) undergoing an elective
procedure requiring iodinated contrast administration did
not find a difference between intravenous 0.9% NaCl hy-
dration versus no hydration.22 Thus, the potential benefit of
hydration in patients with reduced kidney function under-
going EVAR is not clear and should be further evaluated.
In evaluating potential risk factors for EVAR associated
AKI, the present study found several important independent
factors that have not been described previously: pre-
operative use of AT II blockers and peri-operative compli-
cations. In addition, the pre-operative use of statins
appeared to be a protective factor. Operative complications,
as described in the study protocol, can affect renal function
in several ways, including, for example, peri-operative hy-
potension due to bleeding,23 and more pronounced peri-
renal manipulation in treating a type I endoleak or addi-
tional renal stenting.
The potential negative effect of AT II blockers on short-
term kidney function has been described previously in the
coronary setting. Rim et al. reported a propensity matched
study looking at the effect of renineangiotensinealdoste-
rone system blockade on AKI in patients who underwent
coronary angiography.24 This study used the same AKI
criteria as the present study and in 1322 propensity
matched patients found that ACEi/angiotensin receptor
blocker (ARB) recipients had a significantly increased risk of
AKI (11.4% vs. 6.3%). The investigators showed that use of
ACEi/ARBs was an independent risk factor for AKI occur-
rence associated with coronary angiography.
In concordance with the finding that AT II blocker and not
ACEi was associated with AKI, Peng et al. reported a
Table 2. Risk factor analysis of the development of acute kidney failure (AKI) after endovascular aneurysm repair.
Note. OR ¼ odds ratio; CI ¼ confidence interval; GFR ¼ glomerular filtration rate; ACE ¼ angiotensin converting enzyme. a OR adjusted for
age and sex. b OR adjusted for age, sex, coronary disease, and diabetes mellitus. c OR adjusted for age, sex, renal artery stenosis, and
carbasalate calcium. d OR adjusted for age, sex, hypertension, coronary disease, ACE inhibitor, and angiotensin receptor blocker. e OR
adjusted for age, sex, hypertension, coronary disease, angiotensin receptor blocker. fOR adjusted for age, sex, hypertension, coronary
disease, and ACE inhibitor.
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Table 3. Risk factor analysis of renal function decline after endovasculair aneurysm repair (EVAR).
Baseline HR 95% CI p
Age (y) 1.02 0.97 – 1.06 .53
Male sex 1.16 0.50 – 2.65 .73
GFR per mL/min increase 0.99 0.98 – 1.01 .47
AKI after EVAR 2.35 1.09 – 5.07 .03
Pre- and peri-operative
Diameter aorta per cm increase 1.00 1.02 – 1.11 .01
Thrombus SR 1.92 0.90 – 4.09 .09
Diameter neck per mm increase 1.13 1.02 – 1.25 .02
Renal artery stenosis 2.38 1.17 – 4.88 .02
Accessory renal artery coverage 1.70 0.71 – 4.11 .24
Endoleak Not estimable – .70
Re-intervention 1.47 0.61 – 3.55 .39
Number contrast administrations 0.91 0.73 – 1.15 .44
Comorbidities
Hypertension 1.63 0.71 – 3.74 .25
Diabetes mellitus 1.13 0.53 – 2.42 .75
Coronary disease 0.61 0.31 – 1.22 .16
Heart failure 2.67 1.11 – 6.45 .03
Stroke 0.56 0.17 – 1.82 .33
Peripheral arterial occlusive disease 1.02 0.42 – 2.46 .97
Adjusted analysis
AKI after EVAR a 2.19 0.99 – 4.85 .05
Diameter neck b 1.13 1.02 – 1.25 .02
Renal artery stenosis c 2.24 1.05 – 4.79 .04
Decreased CKD risk    Increased CKD risk
0 .1 1 1 0
Note. HR ¼ hazard ratio; CI ¼ confidence interval; GFR ¼ glomerular filtration rate; AKI ¼ acute kidney injury; SR ¼ ??; CKD ¼ chronic
kidney disease. a HR adjusted for age, sex, renal artery stenosis, thrombus. b HR adjusted for age and sex.cHR adjusted for age, sex,
hypertension, thrombus, and diabetes mellitus.
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analysis of 14 qualifying trials.25 There was an overall 1.28
fold increased risk of contrast induced AKI in patients taking
ACEi or ARBs. However, subgroup analysis identified a
significantly increased risk of contrast induced AKI in pa-
tients taking ARBs (OR 3.31) compared with patients taking
ACEIs (OR 0.86). Considering that other studies have also
demonstrated a protective effect of renineangiotensin
system inhibitors on AKI,26 it is clear that more studies are
needed to clarify the published discrepancies and to further
explore the effect of AT II blockers in the EVAR setting.
Although statin use has been shown to protect renal
function in open aneurysm repair with suprarenal clamp-
ing,27 this has not been described before in the EVARsetting. However, there is a great body of research in this
field in the coronary intervention setting, demonstrating a
protective effect.28 It is clear that more data are needed to
further delineate the effect of statins in AKI prevention
following EVAR.
The other important finding of the present study is that
EVAR was associated with a significant increase in clinically
relevant renal function decline at 2 years (23.5%) as
compared with untreated aneurysm patients (6.7%). The
possibility of EVAR associated deterioration in kidney func-
tion has recently been emphasized. Karthikesalingam et al.
analysed the literature on renal function after EVAR and
reported in a systematic review and meta-analysis that,
overall there is significant reduction in GFR in the follow-up
Acute kidney injury and renal function decline after EVAR 719period.10 Surprisingly, a study on renal function based on the
UK EVAR trials reported limited renal function decline over
time.29 This study used a multilevel modelling of eGFR,
measured annually over an average of 3.6 years and included
1194 patients enrolled in the EVAR trials to compare renal
function in patients managed by open or endovascular
repair. The mean rate of change in eGFR was around e1 mL/
minute/1.73 m2 per year. Most studies, as reported in the
systematic review of Karthikesalingam et al.,10 evaluated
renal function decline to compare EVARwith open aneurysm
repair,30 or to compare infrarenal with suprarenal fixa-
tion.9,14 In order to more precisely assess whether EVAR and
subsequent contrast administrations affect long-term renal
function, a control group of untreated aneurysm patients
with a similar cardiovascular risk profile was included.
Aneurysm patients are older and have a high burden of
cardiovascular comorbidities with common prevalence of
hypertension. Thus, it could be speculated that this group of
patients is at increased risk of renal function decline over
time. In this regard, it should be noted that ageing by itself is
associated with a decline in GFR and in the age group of 70e
80 years a slope of 1.49 mL/ minute decrease per year has
been described.31 In addition, to study the occurrence of
clinically important renal function decline, with the inherent
variability of creatinine when interpreting change in eGFR,
the KDIGO clinical practice guidelines were used to define
renal function deterioration.13
Interestingly, as was shown in the UK EVAR renal function
study,29 larger aortic neck diameter emerged as a significant
risk factor for renal function decline. Whether this effect is
mediated by increased probability of subsequent graft
related complications for larger necks is unknown. There
was also an indication for an effect of renal artery stenosis
and the occurrence of AKI as risk factors for subsequent
renal function decline. The presence of significant renal
artery stenosis as a potential risk factor for renal function
decline after EVAR has not been described previously. In the
CORAL study (effect of renal stenting), which defined pro-
gressive renal insufficiency as a reduction from baseline of
30% in the eGFR at 2 years, about 15% of patients reached
this primary outcome. This adverse renal outcome could not
be prevented by renal artery stenting.32 Although the pre-
sent patient data are not compared with the study popu-
lation of the CORAL investigation, a similar magnitude of
renal function decline with a pronounced effect in patients
with renal artery stenosis was found. The mechanism of this
finding is unclear and merits further evaluation. Although
stent grafts with suprarenal fixation have not consistently
been shown to affect renal function versus stent grafts
without suprarenal fixation,9,14 the impact of the struts on
an atherosclerotic stenotic renal artery has not been thor-
oughly examined. Based on the present findings it can be
argued that patients at risk of renal function deterioration
should be monitored more closely and would require
nephrological consultation to evaluate means to protect the
kidney.33 These aspects are not routinely employed in
aneurysm practice today and highlight the importance of
the current findings.Some limitations need to be addressed. First, the limited
number of patients in the present study population reduced
the power. For AKI analysis, multiple candidate risk factors
were selected of which five resulted in an association with
AKI (baseline creatinine, complications during operation,
presence of a suprarenal thrombus, not using statins, or use
of an AT II blocker). Because multiple risk factors were
tested with a limited sample size, it is possible that a false
positive risk factor was found. However, as a sensitivity
analysis, several multivariate analyses were performed to
adjust for important confounders, after which only renal
artery stenosis was not associated with AKI and all other
risk factors remained associated. This does not rule out that
there was residual confounding, which may have biased the
results. Second, using a cohort study it is hard to prove a
causal relationship for the development of both AKI and
clinically relevant renal function decline (because of con-
founding by indication). Nevertheless, it has been shown
that, for example, patients on AT II blockers are at risk of
developing AKI, whereas further research is necessary to
prove causality. Therefore, it is believed that the present
results give guidance in identifying patients at high risk of
developing both AKI and clinically relevant renal function
decline.
CONCLUSION
This study identified the use of an AT II blocker and peri-
operative complications as important risk factors for the
occurrence of EVAR associated AKI. This finding could help
to implement preventive measures to reduce AKI, which
should be addressed in further studies. Furthermore, as
compared with a control group of untreated aneurysm
patients, the problem of renal function decline after EVAR is
highlighted. Patients with renal artery stenosis and AKI
following EVAR were shown to be at high risk of developing
chronic renal function decline, which indicates that in these
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